Qiagen NV (QGEN) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Qiagen NV stock $38.89, price $50.33, that is 22.7% below the price, quality 77 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range $30.70 – $52.40 · fair‑value band $25.92 – $49.59 · the $50.33 price screens above the $38.89 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 8, 2026.
Follow Qiagen in your weekly email
Every Wednesday you see whether Qiagen is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide.
Show moreShow less
The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories.
It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing.
The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions.
It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service.
It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Stock analysis
Qiagen NV (QGEN) currently trades at $50.33, while our model-based Fair Value estimate is $38.89, 23% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $44.93 per share, and 0 of the 26 models we run sit above the $50.33 price.
Bear case: the Dividend Discount group reads lowest at $5.26, and 26 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: $25.92 (bear) to $49.59 (bull), the price of $50.33 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 77/100 (high quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Qiagen NV reported revenue of $2.1B in FY2025 versus $2.3B in FY2021, a compound −1.8%/yr. Reported net income was $425M in FY2025, compounding −4.6%/yr from FY2021.
Key figures
Market cap $10.5B Large · P/E ratio 27.2 · P/S ratio 4.94 · EPS (TTM) $1.85 · Dividend yield 0.7% · Net margin 18.2% · Return on equity 10.8% · Return on assets (EBIT) 7.1% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 67 out of 100 (low confidence).
What moves the price
The share trades about 4% below its 52-week high and 64% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at −23%, QGEN screens richer than that median.
Fair Value models
Bear$25.92Fair Value $38.89Bull$49.59
Price $50.33 · Downside -22.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($1.28 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.67/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+5.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.2%
Start year 2020 (pandemic). Over 10 years: +5.0% a year
Revenue growth 30 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+6.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+6.0%
Dividend (yield on the price)0.7%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.1.2% vs 15.1%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.21% → 25%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+9.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +6.4% a year for the price and +1.6% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (99 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
AI conclusion: Decades of molecular expertise and a large knowledge base form Qiagen's core strength, yet thin evidence and low returns on equity remain its main weak point.
Main risk: Faster AI-driven alternatives could erode demand for Qiagen's sample-prep and testing offerings and hit its core revenue streams.
Qiagen builds its diagnostics and research tools on decades of molecular expertise. Recent AI additions let researchers query biological data in natural language while tracing evidence back to its 25-year knowledge base used by 150,000 people. Our models see it as overvalued. Will the core sample-prep and testing business gain more from these tools than it risks losing to faster AI-driven alternatives?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks
Beats the industry median on 10/15 measures
Overall it ranks above its industry peers.
Valuation
Quality Score77 · Top 25%
Fair Value upside−22.7% · Above median
Profitability
Return on equity (12 months)10.8% · Above median
Return on assets6.8% · Top 25%
Net margin (12 months)18.2% · Top 25%
Operating margin (12 months)27.7% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)2.9% · Below median
Dividend yield (12 months)0.7% · Below median
Balance sheet
Debt / equity0.44× · Highest 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/E (12 months)27.2× · Cheaper than median
P/B2.77× · Pricier than median
P/S (12 months)4.94× · Pricier than median
Price / free cash flow (fiscal year)23.1× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Qiagen NV Fair Value". https://www.fairvalue-calculator.com/stock/QGEN
Frequently asked questions
Is Qiagen NV (QGEN) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $38.89 versus a price of $50.33, about 23% lower (overvalued).
What is the fair value of QGEN?
Our model-based fair value for Qiagen NV is $38.89 (as of Nov 8, 2026), built from audited fundamentals. The current price: $50.33.
What is the quality score of QGEN?
Qiagen NV has a Quality Score of 77/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Qiagen NV (QGEN)?
Our model-based price target is the fair value of $38.89 (as of Nov 8, 2026) from 26 valuation models. Cautious scenario $25.92, optimistic scenario $49.59. It is a calculation from audited fundamentals, not an analyst target.
What is the Qiagen NV stock forecast for 2026?
Our models put fair value at $38.89, about 23% lower versus a price of $50.33 (overvalued). Cautious scenario $25.92, optimistic scenario $49.59. The calculation is refreshed regularly with new filings.
What is the revenue of Qiagen NV (QGEN)?
Qiagen NV reported trailing-twelve-month revenue of about $2.1B (latest available figure, as of Nov 8, 2026).
Does Qiagen NV pay a dividend?
Qiagen NV currently shows a dividend yield of 0.70% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Qiagen NV (QGEN) and when is the ex-dividend date?
Qiagen NV pays a dividend of $0.35 per share a year, a dividend yield of 0.7%. The last ex-dividend date was Jul 7, 2026. The payout ratio is 18.9% of earnings. Free cash flow covers the dividend 6.27 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Qiagen NV (QGEN)?
For today's price to be fair in a discounted-cash-flow model, Qiagen NV would have to grow free cash flow by +9.0 % per year for five years (discount rate 8.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +2.3 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of QGEN use?
Our models discount Qiagen NV at 8.2 %: a base by market capitalisation (large), damped by beta 0.56, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Qiagen NV that is +9.0 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.2 %) and the same formula as our fair value.
How much growth has Qiagen NV (QGEN) delivered so far?
Over the past 5 years revenue at Qiagen NV grew +2.3 % a year. The price currently implies free-cash-flow growth of +9.0 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Qiagen NV (QGEN) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Qiagen NV (+9.0 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Qiagen NV (QGEN)?
The free-cash-flow yield on the price is 4.33 %: that much free cash flow Qiagen NV produces per unit of market value. When it exceeds the discount rate of our models (8.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Qiagen NV (QGEN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Qiagen NV it is $38.89 per share (as of Nov 8, 2026), against a price of $50.33. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Qiagen NV stock overvalued or undervalued in 2026?
As of Nov 8, 2026, QGEN trades above its calculated fair value: price $50.33, fair value $38.89, a gap of about −23% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of QGEN?
No. The price is what the market pays today ($50.33); the fair value is what the company's own numbers justify ($38.89). For Qiagen NV the two are $11.44 per share apart. That gap is exactly why we show both numbers side by side.
How much is Qiagen NV worth?
The market values Qiagen NV at about $10.5B (market capitalisation, as of Nov 8, 2026). Per share that is $50.33; our models calculate a fair value of $38.89 per share.
What do the bullish and bearish scenarios say about QGEN?
Our models span a range for Qiagen NV: cautious scenario $25.92, base $38.89, optimistic $49.59 per share (as of Nov 8, 2026, price $50.33). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of QGEN?
Qiagen NV trades at a price-to-earnings ratio of 27.2 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $38.89 is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2017 to 2025), reported earnings, 6 of the years ex one-offs: 34.5. Other multiples: PEG 1.3, P/B 2.8, P/S 4.9, EV/EBITDA 15.0.
What is the PEG ratio of QGEN?
The PEG ratio of Qiagen NV is 1.34 (P/E divided by earnings growth, as of Nov 8, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Qiagen NV (QGEN)?
Balance-sheet figures for Qiagen NV (as of Nov 8, 2026): return on equity 10.8%, debt of 0.44 per unit of equity. They feed the Quality Score of 77/100, which measures business quality independently of the share price.
How far is QGEN from its 52-week high?
Qiagen NV trades at $50.33, about 4% below its 52-week high of $52.40 and 64% above the low of $30.72 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $38.89 is for.
Which stocks are comparable to Qiagen NV?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Qiagen NV stock attractive at the current price?
The data as of Nov 8, 2026: price $50.33, calculated fair value $38.89 (−23%), Quality Score 77/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of QGEN calculated?
We run Qiagen NV through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $38.89 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Qiagen NV itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Qiagen NV (QGEN)?
The closing price on Nov 6, 2026 was $50.33. Our model-based fair value is $38.89, about 23% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Qiagen NV right now?
A high-quality business (quality 77/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. A fairly wide model range ($25.92 to $49.59) leaves room in how you read the outcome.
Where does the earnings growth of Qiagen NV (QGEN) come from?
Earnings per share at Qiagen NV grew +12.1 % a year from 2014 to 2025. Broken into its drivers: revenue per share +5.6 %, EBIT margin +4.9 %, tax rate −2.7 %, residual (interest, one-offs) +4.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Qiagen NV
How large is the market capitalisation of Qiagen NV (QGEN)?
The market capitalisation of Qiagen NV is $10.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Qiagen NV (QGEN)?
The price-to-sales ratio of Qiagen NV is 4.94 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Qiagen NV (QGEN)?
Earnings per share at Qiagen NV are $1.85 (price ÷ EPS = P/E 27.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Qiagen NV (QGEN)?
The dividend yield of Qiagen NV is 0.7% (payout 18.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Qiagen NV (QGEN)?
The net margin of Qiagen NV is 18.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Qiagen NV (QGEN)?
The return on equity (ROE) of Qiagen NV is 10.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Qiagen NV (QGEN)?
On an EBIT basis the return on assets of Qiagen NV is 7.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Qiagen NV (QGEN)?
The operating margin of Qiagen NV is 27.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Qiagen NV (QGEN)?
Revenue at Qiagen NV is growing +2.9% versus a year earlier (3y avg −0.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Qiagen NV (QGEN)?
Earnings per share at Qiagen NV are growing −19.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Qiagen NV (QGEN) carry?
The net debt of Qiagen NV is $815M (fiscal year 2025, ≈ 1.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Qiagen NV in the live analysis
One click puts Qiagen NV on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 8, 2026